Resmonics, a Zurich-based start-up that was only just created in 2020, has received financial support from CSS Insurance in a pre-seed financing round. According to a press release from Resmonics, this will be used to accelerate development of its first product and to certify it as a medical device. This product is a smartphone-based digital biomarker service for people with asthma or COPD (chronic obstructive pulmonary disease). Resmonics plans to use the secured investment from CSS to enter the Swiss and European markets in Q3 2021.
Peter Tinschert, CEO and Founder of Resmonics is quoted in the press release, saying: “We are very excited to have attracted CSS Insurance, one of the leading players in the Swiss healthcare market, as our first investor. Their profound understanding of the evolving digital health market and strong network puts us in a unique position to grow Resmonics beyond the Swiss market.”
CSS has already known the founding team of Resmonics for several years now from their work at the CSS Health Lab, where CSS is working on “digital pills” with the Swiss Federal Institute of Technology in Zurich and the University of St.Gallen. Peter Mittemeyer, Head of Strategy & Corporate Services as well as Member of the Corporate Executive Committee at CSS Insurance, adds: “Resmonics has developed an innovative and fully scalable technology for addressing a global health challenge – the management of chronic respiratory diseases.”